FindTrial
Sign In

An observational study for idiopathic inflammatory demyelination disease in central nervous system: Screening Biomarkers and Clinical Evaluation

An observational study for idiopathic inflammatory demyelination disease in central nervous system: Screening for Biomarkers and Clinical Evaluation

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900023265
Enrollment
Unknown
Registered
2019-05-19
Start date
2019-06-01
Completion date
Unknown
Last updated
2019-05-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

idiopathic inflammatory demyelination disease

Interventions

Gold Standard:Clinical outcome
Index test:biomarkers

Sponsors

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Aged > 18 years; 2. From January 2013 to January 2023, patients with IIDD or non-central nervous system inflammatory demyelination were diagnosed in the Department of Neurology of our hospital.

Exclusion criteria

Exclusion criteria: 1. Patients with infections in the central nervous system, lungs or other systems; 2. Secondary central nervous system demyelination damage, such as vasculitis, systemic lupus erythematosus and Sjogren's syndrome; 3. Patients with vascular (including bleeding and ischemia), genetic metabolic, neoplastic or toxic diseases.

Design outcomes

Primary

MeasureTime frame
Expanded Disability Status Scale (EDSS) score;—

Countries

China

Contacts

Public ContactDai-Shi Tian

Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology

tiandaishi@126.com+86 027-83663337

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026